Jeil Pharma Holdings Inc (KRX:002620)
South Korea · Delayed Price · Currency is KRW 7,500.00
-140.00 (-1.83%)
Last updated: Aug 24, 2026, 9:43 AM KST
Jeil Pharma Holdings Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 117,283 | 123,423 | 120,046 | 180,683 | 236,407 | 245,618 | |
Market Cap Growth | -11.16% | 2.81% | -33.56% | -23.57% | -3.75% | -24.53% |
Enterprise Value | 370,709 | 363,252 | 328,142 | 429,021 | 424,544 | 404,795 |
Last Close Price | 7640.00 | 8040.00 | 7753.08 | 11596.16 | 15107.77 | 15636.92 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 13.92 | 8.43 | - | - | - | - |
PS Ratio | 0.19 | 0.19 | 0.15 | 0.23 | 0.30 | 0.32 |
PB Ratio | 0.25 | 0.26 | 0.27 | 0.45 | 0.56 | 0.49 |
P/TBV Ratio | 0.38 | 0.40 | 0.40 | 0.67 | 0.91 | 0.96 |
P/FCF Ratio | - | - | 593.17 | - | - | - |
P/OCF Ratio | 9.89 | 316.26 | 26.43 | - | - | 18.33 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.59 | 0.55 | 0.42 | 0.53 | 0.54 | 0.53 |
EV/EBITDA Ratio | 10.67 | 6.74 | 112.46 | 12.82 | 126.46 | 48721.60 |
EV/EBIT Ratio | 19.09 | 9.32 | - | 20.51 | - | - |
EV/FCF Ratio | - | - | 1621.42 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.36 | 0.36 | 0.36 | 0.53 | 0.39 | 0.23 |
Debt / EBITDA Ratio | 3.33 | 3.10 | 53.19 | 6.40 | 48.44 | 13850.20 |
Debt / FCF Ratio | 68.32 | - | 766.93 | - | - | - |
Net Debt / Equity Ratio | 0.18 | 0.19 | 0.18 | 0.39 | 0.26 | 0.14 |
Net Debt / EBITDA Ratio | 1.69 | 1.63 | 27.19 | 4.63 | 32.53 | 8166.30 |
Net Debt / FCF Ratio | 34.56 | -11.16 | 391.98 | -14.57 | -3.34 | -6.60 |
Asset Turnover | 0.72 | 0.74 | 0.88 | 0.92 | 0.90 | 0.86 |
Inventory Turnover | 3.14 | 3.33 | 4.61 | 4.94 | 5.38 | 4.88 |
Quick Ratio | 0.81 | 0.76 | 0.73 | 0.61 | 0.65 | 0.71 |
Current Ratio | 1.22 | 1.16 | 1.08 | 0.93 | 0.98 | 1.13 |
Return on Equity (ROE) | 7.51% | 7.64% | -15.82% | -3.22% | -18.07% | -2.57% |
Return on Assets (ROA) | 2.54% | 2.76% | -0.79% | 1.50% | -0.54% | -0.63% |
Return on Invested Capital (ROIC) | 5.68% | 6.39% | -2.08% | 3.85% | -1.38% | -1.51% |
Return on Capital Employed (ROCE) | 6.30% | 7.00% | -2.20% | 4.50% | -1.50% | -1.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 7.19% | 11.86% | -42.62% | -8.99% | -31.54% | -1.42% |
FCF Yield | -0.77% | -6.40% | 0.17% | -5.89% | -13.84% | -4.19% |
Dividend Yield | 0.67% | - | - | 0.43% | 0.33% | 0.42% |
Payout Ratio | 12.74% | 1.25% | - | - | - | - |
Buyback Yield / Dilution | -0.13% | -0.01% | 0.01% | - | - | - |
Total Shareholder Return | 0.54% | -0.01% | 0.01% | 0.43% | 0.33% | 0.42% |